Problem 01-15 (algo) Approximately 14 million Americans are addicted to drugs and alcohol. The federal government estimates that these addicts cost the U.S. economy $300 billion in medical expenses and lost productivity. Despite the enormous potential market, many biotech companies have shied away from funding research and development (R&D) initiatives to find a cure for drug and alcohol addiction. Your firm - Drug Abuse Sciences (DAS) - is a notable exception. It has spent $260 million to date working on a cure, but is now at a crossroads. It can either abandon its program or invest another $70 million today. Unfortunately, the firm's opportunity cost of funds is 5 percent and it will take another five years before final approval from the Federal Drug Administration is achieved and the product is actually sold. Expected (year-end) profits from selling the drug are presented in the accompanying table. What is the net present value of the project? Instructions: Enter your response rounded to the nearest penny (two decimal places). Use a negative sign (-) where appropriate. $26557759.86 ✪ Should DAS continue with its plan to bring the drug to market, or should it abandon the project? Continue Year 1 $0 Year 2 $0 Year 3 $0 Year 4 $0 Year 5 $16,400,000 Year 6 $18,300,000 Year 7 $21,300,000 Year 8 $24,700,000 Year 9 $27,100,000
Problem 01-15 (algo) Approximately 14 million Americans are addicted to drugs and alcohol. The federal government estimates that these addicts cost the U.S. economy $300 billion in medical expenses and lost productivity. Despite the enormous potential market, many biotech companies have shied away from funding research and development (R&D) initiatives to find a cure for drug and alcohol addiction. Your firm - Drug Abuse Sciences (DAS) - is a notable exception. It has spent $260 million to date working on a cure, but is now at a crossroads. It can either abandon its program or invest another $70 million today. Unfortunately, the firm's opportunity cost of funds is 5 percent and it will take another five years before final approval from the Federal Drug Administration is achieved and the product is actually sold. Expected (year-end) profits from selling the drug are presented in the accompanying table. What is the net present value of the project? Instructions: Enter your response rounded to the nearest penny (two decimal places). Use a negative sign (-) where appropriate. $26557759.86 ✪ Should DAS continue with its plan to bring the drug to market, or should it abandon the project? Continue Year 1 $0 Year 2 $0 Year 3 $0 Year 4 $0 Year 5 $16,400,000 Year 6 $18,300,000 Year 7 $21,300,000 Year 8 $24,700,000 Year 9 $27,100,000
Chapter6: Population Health
Section: Chapter Questions
Problem 3QAP
Question
Please solve it by yourself with proper explanation and calculation don't use ai
![Problem 01-15 (algo)
Approximately 14 million Americans are addicted to drugs and alcohol. The federal government estimates that these addicts cost the
U.S. economy $300 billion in medical expenses and lost productivity. Despite the enormous potential market, many biotech companies
have shied away from funding research and development (R&D) initiatives to find a cure for drug and alcohol addiction. Your firm -
Drug Abuse Sciences (DAS) - is a notable exception. It has spent $260 million to date working on a cure, but is now at a crossroads. It
can either abandon its program or invest another $70 million today. Unfortunately, the firm's opportunity cost of funds is 5 percent and
it will take another five years before final approval from the Federal Drug Administration is achieved and the product is actually sold.
Expected (year-end) profits from selling the drug are presented in the accompanying table.
What is the net present value of the project?
Instructions: Enter your response rounded to the nearest penny (two decimal places). Use a negative sign (-) where appropriate.
$26557759.86 ✪
Should DAS continue with its plan to bring the drug to market, or should it abandon the project?
Continue
Year 1
$0
Year 2
$0
Year 3
$0
Year 4
$0
Year 5
$16,400,000
Year 6
$18,300,000
Year 7
$21,300,000
Year 8
$24,700,000
Year 9
$27,100,000](/v2/_next/image?url=https%3A%2F%2Fcontent.bartleby.com%2Fqna-images%2Fquestion%2Fc6f082eb-4ce1-4238-a962-674f668a61b4%2F88b964a7-3b20-4c16-8728-b0db03b614fd%2Fkl8ose_processed.jpeg&w=3840&q=75)
Transcribed Image Text:Problem 01-15 (algo)
Approximately 14 million Americans are addicted to drugs and alcohol. The federal government estimates that these addicts cost the
U.S. economy $300 billion in medical expenses and lost productivity. Despite the enormous potential market, many biotech companies
have shied away from funding research and development (R&D) initiatives to find a cure for drug and alcohol addiction. Your firm -
Drug Abuse Sciences (DAS) - is a notable exception. It has spent $260 million to date working on a cure, but is now at a crossroads. It
can either abandon its program or invest another $70 million today. Unfortunately, the firm's opportunity cost of funds is 5 percent and
it will take another five years before final approval from the Federal Drug Administration is achieved and the product is actually sold.
Expected (year-end) profits from selling the drug are presented in the accompanying table.
What is the net present value of the project?
Instructions: Enter your response rounded to the nearest penny (two decimal places). Use a negative sign (-) where appropriate.
$26557759.86 ✪
Should DAS continue with its plan to bring the drug to market, or should it abandon the project?
Continue
Year 1
$0
Year 2
$0
Year 3
$0
Year 4
$0
Year 5
$16,400,000
Year 6
$18,300,000
Year 7
$21,300,000
Year 8
$24,700,000
Year 9
$27,100,000
Expert Solution
![](/static/compass_v2/shared-icons/check-mark.png)
This question has been solved!
Explore an expertly crafted, step-by-step solution for a thorough understanding of key concepts.
Step by step
Solved in 2 steps with 1 images
![Blurred answer](/static/compass_v2/solution-images/blurred-answer.jpg)
Recommended textbooks for you
![EBK HEALTH ECONOMICS AND POLICY](https://www.bartleby.com/isbn_cover_images/9781337668279/9781337668279_smallCoverImage.jpg)
![EBK HEALTH ECONOMICS AND POLICY](https://www.bartleby.com/isbn_cover_images/9781337668279/9781337668279_smallCoverImage.jpg)